Xiaoyong Bao, PhD
University of Texas Medical Branch at Galveston
Research Project:
Targeting Protein That Regulates SARS-CoV-2 Could Lead to Better COVID-19 Treatments
Grant Awarded:
- Emerging Respiratory Pathogen Award
Research Topics:
- combination therapies experimental therapeutics
- immunology immunotherapy
- pathology
Research Diseases:
- COVID-19
- pneumonia
- respiratory viruses
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant illness and death worldwide. New SARS-CoV-2 variants have been shown to evade vaccines and treatments that directly target viruses of the previous generation. This highlights the urgent need to discover therapeutic targets that can lead to effective treatments unaffected by virus mutations. We are researching the role of a protein called exchange protein directly activated by cAMP 1 (EPAC1), a novel host regulator of SARS-CoV-2 infection, in controlling replication of the virus and associated inflammation. The results of this project should provide valuable insights that can aid in developing novel treatments against SARS-CoV-2.
Page last updated: October 7, 2024
Today Only: Your Gift Goes 5X Further!
Donate before midnight and your generosity will be multiplied 5X to help people facing lung disease in the year ahead.
Donations support American Lung Association's entire mission and will not be designated to a specific program or location.
